DK3023100T3 - Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer - Google Patents
Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer Download PDFInfo
- Publication number
- DK3023100T3 DK3023100T3 DK14826652.1T DK14826652T DK3023100T3 DK 3023100 T3 DK3023100 T3 DK 3023100T3 DK 14826652 T DK14826652 T DK 14826652T DK 3023100 T3 DK3023100 T3 DK 3023100T3
- Authority
- DK
- Denmark
- Prior art keywords
- antitum
- fgfr
- harmful
- medicine
- intermitting
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013149963 | 2013-07-18 | ||
| PCT/JP2014/069086 WO2015008839A1 (ja) | 2013-07-18 | 2014-07-17 | Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3023100T3 true DK3023100T3 (da) | 2019-05-27 |
Family
ID=52346281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14826652.1T DK3023100T3 (da) | 2013-07-18 | 2014-07-17 | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160193210A1 (da) |
| EP (1) | EP3023100B1 (da) |
| JP (1) | JP6084291B2 (da) |
| KR (1) | KR101974254B1 (da) |
| AU (1) | AU2014291161B2 (da) |
| DK (1) | DK3023100T3 (da) |
| ES (1) | ES2724929T3 (da) |
| HU (1) | HUE044273T2 (da) |
| PL (1) | PL3023100T3 (da) |
| PT (1) | PT3023100T (da) |
| RU (1) | RU2664118C2 (da) |
| TR (1) | TR201907147T4 (da) |
| TW (1) | TWI574691B (da) |
| WO (1) | WO2015008839A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3023100T (pt) | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| CN105837575B (zh) | 2015-01-13 | 2019-01-15 | 四川大学 | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 |
| SG11201707384YA (en) * | 2015-03-31 | 2017-10-30 | Taiho Pharmaceutical Co Ltd | Crystal of 3,5-disubstituted benzene alkynyl compound |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| CN107698593A (zh) | 2016-08-09 | 2018-02-16 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN107840842A (zh) | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
| WO2019181876A1 (ja) | 2018-03-19 | 2019-09-26 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| KR20210088651A (ko) | 2018-11-09 | 2021-07-14 | 다이호야쿠힌고교 가부시키가이샤 | 디메톡시벤젠 화합물의 제조 방법 |
| EP3882248A4 (en) | 2018-11-09 | 2022-07-06 | Taiho Pharmaceutical Co., Ltd. | DIMETHOXYBENZENE COMPOUND ANALOGUES, METHODS FOR ANALYZING SUCH COMPOUNDS AND STANDARD PRODUCTS OF SUCH COMPOUNDS |
| US20220023300A1 (en) * | 2018-11-26 | 2022-01-27 | Taiho Pharmaceutical Co., Ltd. | Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy |
| WO2020170355A1 (ja) * | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| JP2022548067A (ja) * | 2019-09-11 | 2022-11-16 | テンノア・セラピューティクス・（スージョウ）・リミテッド | 細菌感染症を治療するためのペナム誘導体 |
| US20230165862A1 (en) * | 2020-04-10 | 2023-06-01 | Taiho Pharmaceutical Co., Ltd. | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
| JP2023528880A (ja) * | 2020-06-05 | 2023-07-06 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| CN116057045A (zh) | 2020-06-05 | 2023-05-02 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| TWI797711B (zh) * | 2020-08-13 | 2023-04-01 | 大陸商上海和譽生物醫藥科技有限公司 | 一種fgfr及其突變抑制劑，其製備方法和應用 |
| CN114805359B (zh) * | 2021-01-28 | 2023-10-27 | 药雅科技(上海)有限公司 | 炔代杂环化合物fgfr抑制剂的制备方法和用途 |
| CN115028634B (zh) * | 2021-03-08 | 2023-11-28 | 药雅科技(上海)有限公司 | 一种炔代吡嗪并杂环类fgfr抑制剂及其制备方法和用途 |
| CN115785103A (zh) * | 2022-12-28 | 2023-03-14 | 北京康立生医药技术开发有限公司 | 一种治疗胆管癌药物福巴替尼的合成方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005007083A2 (en) | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| KR20060096487A (ko) | 2003-10-27 | 2006-09-11 | 진랩스 테크놀러지스, 인크. | 바이러스 감염증들을 치료하기 위한 뉴클레오시드 화합물 |
| CN101321760A (zh) * | 2005-10-06 | 2008-12-10 | 先灵公司 | 作为蛋白激酶抑制剂的吡唑并嘧啶 |
| ZA200804498B (en) * | 2005-11-15 | 2009-07-29 | Array Biopharma Inc | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| CA2641254A1 (en) | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
| US20100273776A1 (en) | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| EP1939197A1 (en) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| EP2954900A1 (en) * | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| JP2011524888A (ja) | 2008-06-19 | 2011-09-08 | アストラゼネカ アクチボラグ | ピラゾール化合物４３６ |
| GB0819105D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| PL2424843T3 (pl) * | 2009-04-30 | 2014-07-31 | Novartis Ag | Pochodne imidazolowe i ich zastosowanie jako modulatorów kinaz zależnych od cykliny |
| KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| EP2547698B1 (en) | 2010-03-14 | 2015-07-29 | The Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| DE102011015188A1 (de) | 2010-03-29 | 2011-09-29 | Herbert Kannegiesser Gmbh | Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen |
| CA3113343A1 (en) * | 2010-06-03 | 2011-12-08 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma |
| MY163187A (en) | 2011-04-06 | 2017-08-15 | Taiho Pharmaceutical Co Ltd | Novel imidazo-oxazine compound or salt thereof |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物及びその塩 |
| US9475815B2 (en) | 2012-02-23 | 2016-10-25 | Bayer Intelletual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| HUE036188T2 (hu) | 2012-07-02 | 2018-06-28 | Taiho Pharmaceutical Co Ltd | Egy imidazooxazin vegyületet tartalmazó tumorellenes hatás potenciátor |
| EP2692740A1 (en) | 2012-07-30 | 2014-02-05 | Le Centre National De La Recherche Scientifique | Glycan compositions, processes for preparing the same and their uses as a drug |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| WO2014203959A1 (ja) | 2013-06-20 | 2014-12-24 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| PT3023100T (pt) | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| KR102478887B1 (ko) | 2014-04-25 | 2022-12-16 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물을 고용량 함유하는 제제 |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN105859721B (zh) | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| CN111943962A (zh) | 2015-02-27 | 2020-11-17 | 大鹏药品工业株式会社 | 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
| SG11201707384YA (en) | 2015-03-31 | 2017-10-30 | Taiho Pharmaceutical Co Ltd | Crystal of 3,5-disubstituted benzene alkynyl compound |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN108289892B (zh) | 2015-06-29 | 2021-11-23 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
-
2014
- 2014-07-17 PT PT14826652T patent/PT3023100T/pt unknown
- 2014-07-17 EP EP14826652.1A patent/EP3023100B1/en active Active
- 2014-07-17 HU HUE14826652 patent/HUE044273T2/hu unknown
- 2014-07-17 WO PCT/JP2014/069086 patent/WO2015008839A1/ja active Application Filing
- 2014-07-17 JP JP2015527336A patent/JP6084291B2/ja active Active
- 2014-07-17 TW TW103124539A patent/TWI574691B/zh active
- 2014-07-17 TR TR2019/07147T patent/TR201907147T4/tr unknown
- 2014-07-17 RU RU2016105133A patent/RU2664118C2/ru active
- 2014-07-17 DK DK14826652.1T patent/DK3023100T3/da active
- 2014-07-17 AU AU2014291161A patent/AU2014291161B2/en active Active
- 2014-07-17 ES ES14826652T patent/ES2724929T3/es active Active
- 2014-07-17 KR KR1020167003764A patent/KR101974254B1/ko active IP Right Grant
- 2014-07-17 US US14/905,420 patent/US20160193210A1/en not_active Abandoned
- 2014-07-17 PL PL14826652T patent/PL3023100T3/pl unknown
-
2019
- 2019-02-13 US US16/274,573 patent/US10894048B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE044273T2 (hu) | 2019-10-28 |
| EP3023100A1 (en) | 2016-05-25 |
| TWI574691B (zh) | 2017-03-21 |
| EP3023100A4 (en) | 2017-01-04 |
| JP6084291B2 (ja) | 2017-02-22 |
| TR201907147T4 (tr) | 2019-06-21 |
| KR101974254B1 (ko) | 2019-04-30 |
| EP3023100B1 (en) | 2019-03-13 |
| RU2016105133A (ru) | 2017-08-23 |
| PL3023100T3 (pl) | 2019-07-31 |
| US20160193210A1 (en) | 2016-07-07 |
| WO2015008839A1 (ja) | 2015-01-22 |
| RU2016105133A3 (da) | 2018-02-28 |
| US20190183897A1 (en) | 2019-06-20 |
| AU2014291161B2 (en) | 2018-04-26 |
| US10894048B2 (en) | 2021-01-19 |
| TW201536294A (zh) | 2015-10-01 |
| KR20160032186A (ko) | 2016-03-23 |
| JPWO2015008839A1 (ja) | 2017-03-02 |
| RU2664118C2 (ru) | 2018-08-15 |
| ES2724929T3 (es) | 2019-09-17 |
| PT3023100T (pt) | 2019-05-29 |
| AU2014291161A1 (en) | 2016-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3023100T3 (da) | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| DK2968071T3 (da) | Enhed til oral levering af terapeutiske forbindelser | |
| DK3062849T3 (da) | Medikamentadministrationsanordning | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
| DK2970493T3 (da) | Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler | |
| BR112016009485A2 (pt) | Inalador de medicamento | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3536310T3 (da) | Sprøjte | |
| DK3685826T3 (da) | Sprøjte | |
| DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
| DK2970389T3 (da) | Farmaceutiske forbindelser | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3049117T3 (da) | Ultralydsmedieret afgivelse af lægemidler | |
| DK3287133T3 (da) | Proton-bindende polymerer til oral indgivelse | |
| DK3007726T3 (da) | Fremgangsmåder til behandling af en tauopati | |
| DK3038674T3 (da) | Medikamentafgivelsesindretning | |
| DK3024519T3 (da) | Destruktion af hypodermiske kanyler | |
| DK3363428T3 (da) | Perfusionsdoseringsform | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| DK3021911T3 (da) | Anordning til indgivelse af lægemidler | |
| FI20135231A (fi) | Potilasalusta | |
| DK3065790T3 (da) | Fremgangsmåder til fjernelse af alpha-galactose |